Page 4 - தேசிய மருந்து ப்ரைஸிஂக் அதிகாரம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
NPPA caps prices of medical devices including Pulse Oximeter, BP machine
dnaindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dnaindia.com Daily Mail and Mail on Sunday newspapers.
Oximeters, BP machines to get cheaper as NPPA caps trade margins at 70%
business-standard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from business-standard.com Daily Mail and Mail on Sunday newspapers.
NPPA caps maximum retail price of five medical devices - The Hindu BusinessLine
thehindubusinessline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindubusinessline.com Daily Mail and Mail on Sunday newspapers.
Mansukh Mandaviya takes control over the health and chemicals and fertilizers ministries
thehindubusinessline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindubusinessline.com Daily Mail and Mail on Sunday newspapers.
Synopsis
The National Pharmaceutical Pricing Authority (NPPA) gave its nod to price cap exemption for Torrent’s nasal spray used for pain relief under Para 32 of the Drug Price Control Order (DPCO) 2013, which is applicable when a new drug developed through a unique, indigenous process, is patented under the Indian Patent Act, 1970, and is not produced elsewhere.
Agencies
The country’s drug pricing regulator has granted a rare exemption to
Torrent Pharmaceuticals’ tapendatol nasal spray from price caps, and approved a one-time price hike of 50% from the ceiling for key drugs carbamazepine, ranitidine and ibuprofen.
The National Pharmaceutical Pricing Authority (NPPA) gave its nod to price cap exemption for Torrent’s nasal spray used for pain relief under Para 32 of the Drug Price Control Order (DPCO) 2013, which is applicable when a new drug developed through a unique, indigenous process, is patented under the Indian Patent Act, 1970, and is not produced elsewhere.